Uncategorized
Topical squalamine shows encouraging results in phase 2 studies
VIENNA — Final results of the phase 2 IMPACT study of topical squalamine lactate in the treatment of neovascular AMD showed a trend toward increased efficacy in specific lesion types, according to a speaker. Squalamine is a small molecule that counteracts multiple growth factors implicated in the angiogenic process, including VEGF and PDGF, Jeffrey Heier, MD, said at the American Society of Retina Specialists meeting. The IMPACT study evaluated the effects of OHR-102 (0.2% squalamine lactate ophthalmic solution, Ohr Pharmaceutical) in combination with anti-VEGF in treatment-naïve patients with wet age-related (Read more...)